New Study Shows Obesity Scrambles the Body’s Metabolic Clock
May 19, 2025 / obesity metabolism disruption / liver starvation response / metabolic clock obesity / molecular network timing / hepatic energy regulation
Obesity disrupts the liver’s ability to coordinate metabolic responses to starvation, altering timing but not molecular structure. This discovery highlights temporal vulnerability in obesity, offering new insights into metabolic regulation and disease mechanisms.
Endocrine regulation of metabolic crosstalk between liver and brown adipose tissue by natural active ingredients
May 19, 2025 / liver-BAT crosstalk / natural bioactive compounds / metabolic regulation obesity / brown fat thermogenesis / nutraceutical insulin sensitivity
Natural bioactive compounds like polyphenols and alkaloids modulate liver–brown adipose tissue crosstalk, enhancing thermogenesis, lipid oxidation, and insulin sensitivity. These pathways offer promising nutraceutical strategies to treat obesity and related metabolic disorders through endocrine and metabolic regulation.
How risk factors of metabolic syndrome may contribute to young-onset dementia
May 19, 2025 / metabolic syndrome dementia / young-onset dementia risk / brain health prevention / neuroinflammation cognitive decline / obesity blood pressure glucose
Metabolic syndrome—marked by obesity, high blood pressure, and elevated glucose—correlates with a higher risk of young-onset dementia. The study emphasizes prevention and early intervention to reduce neuroinflammation, protect brain health, and mitigate long-term cognitive decline.
Animal research reveals metabolic differences between tirzepatide and semaglutide
May 14, 2025 / tirzepatide energy expenditure / semaglutide metabolic adaptation / GLP-1 weight loss drugs / fat oxidation obesity treatment / anti-obesity drug comparison
Animal research reveals tirzepatide increases energy expenditure early in treatment, unlike semaglutide, which reduces it. Both drugs enhance fat oxidation but show transient metabolic effects post-treatment, suggesting their weight loss benefits rely on sustained use and appetite suppression.
Excess adiposity and cancer: evaluating a preclinical-clinical obesity framework for risk stratification
May 13, 2024 / preclinical obesity cancer risk / excess adiposity cancer link / obesity classification framework / metabolic dysfunction and cancer / obesity-related cancer prevention
A new study shows excess adiposity increases cancer risk even before metabolic dysfunction occurs, emphasizing the need for early obesity classification and intervention. Preclinical obesity alone significantly elevates risk for metabolically driven cancers like liver, colorectal, and pancreatic cancer.
Diabetes and weight loss drug semaglutide may also treat liver disease
May 13, 2025 / semaglutide liver disease / MASH treatment semaglutide / GLP-1 agonist fatty liver / semaglutide fibrosis reduction / obesity liver health
Semaglutide significantly improves liver outcomes in patients with metabolic dysfunction-associated steatohepatitis (MASH), promoting steatohepatitis resolution and fibrosis reduction. These benefits may stem from weight loss and metabolic improvements, supporting semaglutide’s potential role in treating obesity-related liver disease.
Forge Biologics Announces AAV Development and cGMP Manufacturing Relationship with Fractyl Health to Advance Their Gene Therapy Platform for Patients with Metabolic Diseases
May 14, 2025 / gene therapy obesity / AAV manufacturing diabetes / Rejuva platform metabolic / Forge Biologics Fractyl / scalable genetic medicine
Forge Biologics will support Fractyl Health’s preclinical Rejuva™ gene therapy platform targeting obesity and type 2 diabetes with scalable AAV manufacturing, leveraging its FUEL™ technology to accelerate development of innovative metabolic disease treatments.
Once-daily oral treatment shows positive results in first human study for obesity treatment
May 14, 2025 / oral obesity treatment / SYNT-101 gastric bypass / satiety hormone modulation / non-invasive weight loss / metabolic disease therapy
SYNT-101, a once-daily oral obesity treatment mimicking gastric bypass effects, showed strong safety, satiety hormone modulation, and delayed glucose absorption in first-in-human trials, offering a promising non-invasive alternative to GLP-1 therapies with preserved lean muscle mass.
Second Head-to-head Phase 3 Study of Mazdutide versus Semaglutide Completes First Participant Dosing in Adults in China with Overweight or Obesity Accompanied Fatty Liver Disease (GLORY-3)
May 15, 2025 / mazdutide obesity treatment / GLORY-3 clinical trial / dual GLP-1 GCG agonist / fatty liver disease China / MAFLD weight loss therapy
Innovent’s GLORY-3 Phase 3 trial has begun dosing to compare mazdutide versus semaglutide in Chinese adults with obesity and MAFLD. Mazdutide targets weight and liver fat reduction via dual GLP-1/glucagon receptor activity.
Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments
May 14, 2024 / Novo Nordisk obesity drugs / Septerna GPCR therapies / oral GLP-1 alternatives / cardiometabolic disease treatment / small molecule weight loss
Novo Nordisk and Septerna have partnered to develop oral small molecule therapies targeting GPCRs for obesity, type 2 diabetes, and cardiometabolic diseases, aiming to expand Novo’s portfolio beyond injectables in the competitive GLP-1-driven weight-loss market.
Targeting the chromatin remodeler BAZ2B mitigates hepatic senescence and MASH fibrosis
May 19, 2025 / BAZ2B liver fibrosis / MASH senescence therapy / PPARα lipid metabolism / chromatin remodeling liver / aging-related liver disease
Targeting chromatin remodeler BAZ2B in hepatocytes reduces liver cell senescence and fibrosis in MASH by preserving PPARα-mediated lipid metabolism, highlighting BAZ2B as a promising therapeutic target for age-related liver dysfunction and fibrotic progression.
Effect of dietary approaches to stop hypertension diet on insulin resistance and lipid accumulation product in subjects with metabolic syndrome
May 16, 2025 / DASH diet metabolic syndrome / insulin resistance reduction / lipid accumulation product / cardiovascular risk diet / plant-based diet benefits
A 12-week DASH diet intervention significantly improved insulin resistance markers and lipid accumulation product in individuals with metabolic syndrome, supporting its role in reducing cardiometabolic risk factors. Further research is needed to confirm long-term benefits.
Chronic overwork may lead to changes in brain regions associated with emotion and cognition
May 14, 2025 / chronic overwork brain changes / emotional regulation cognition / long working hours MRI / occupational stress neuroadaptation / middle frontal gyrus volume
Preliminary MRI research links chronic overwork to structural brain changes in regions tied to emotion and cognition, including the middle frontal gyrus and insula, suggesting neuroadaptive responses that may underlie cognitive and emotional health risks from excessive working hours.
Association between triglyceride glucose body mass index and 1 year all cause mortality in stage 4 CKM syndrome patients
May 16, 2025 / TyG-BMI mortality prediction / insulin resistance CKM / stage 4 CKM prognosis / triglyceride glucose index / all-cause mortality biomarker
In stage 4 CKM syndrome patients, lower TyG-BMI levels are significantly associated with increased 180-day and one-year all-cause mortality, suggesting TyG-BMI is a valuable prognostic tool for assessing insulin resistance and mortality risk in advanced CKM.
Scientists Discover Key Gene Impacts Liver Energy Storage, Affecting Metabolic Disease Risk
May 16, 2025 / PPP1R3B gene function / liver energy storage / type 2 diabetes genetics / metabolic disease risk / glycogen vs fat storage
New research identifies the gene PPP1R3B as a key regulator of liver energy storage, influencing whether energy is stored as glycogen or fat—impacting metabolic disease risk, including type 2 diabetes and fatty liver disease.
This Nutrient May Help Lower Metabolic Syndrome Risk by 21%, New Study Suggests
May 16, 2025 / magnesium and metabolic syndrome / magnesium blood levels / magnesium heart health / metabolic syndrome prevention / magnesium intake benefits
A comprehensive meta-analysis shows higher magnesium intake or blood levels may reduce metabolic syndrome risk by 21%. This supports magnesium’s role in preventing cardiometabolic disorders by improving blood pressure, lipid profiles, and glucose regulation.
Poor Cardiometabolic Health in Pregnancy Tied to Higher BP for Young Offspring
May 15, 2025 / ‘maternal cardiometabolic risk / childhood blood pressure / hypertensive pregnancy effects / gestational diabetes outcomes / early life cardiovascular risk
Maternal cardiometabolic conditions—obesity, hypertension, or gestational diabetes—are linked to elevated blood pressure in children as young as 2, with compounded risk when multiple factors are present, underscoring the need for early maternal and pediatric intervention.
Novo Nordisk and Septerna enter $2.2bn cardiometabolic disease partnership
May 16, 2025 / GPCR drug discovery / oral obesity treatment / type 2 diabetes therapy / Novo Septerna partnership / cardiometabolic disease pipeline
Novo Nordisk and Septerna have partnered to develop oral small molecule therapies targeting GPCRs for type 2 diabetes, obesity, and cardiometabolic diseases, aiming to unlock underutilized receptor targets and expand scalable, non-injectable treatment options.
Novo Nordisk Invests $2.2B in Septerna’s Oral Drugs
May 15, 2025 / GPCR drug development / oral GLP-1 therapy / type 2 diabetes treatment / obesity small molecules / Novo Nordisk Septerna deal
Novo Nordisk and Septerna will jointly develop oral small molecule therapies targeting key GPCRs, including GLP-1, GIP, and glucagon receptors, to address obesity, type 2 diabetes, and cardiometabolic diseases under a $2.2B global collaboration agreement.